Primary central nervous system lymphoma in the elderly

Weller, Michael

DOI: https://doi.org/10.1159/000365408

Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-100325
Accepted Version

Originally published at:
DOI: https://doi.org/10.1159/000365408
Primary central nervous system lymphoma in the elderly

Higher age has consistently been identified as a negative prognostic factor in patients with primary central nervous system lymphoma (PCNSL). The inferior outcome in the elderly has often been attributed to less intensive treatment administered, but beyond that, there seems to be a fundamental difference in the response to – or benefit from – treatment in the elderly. In the G-PCNSL-SG-1 trial [1], 126 of 526 eligible patients were aged 70 or more. Their overall response rate was only mildly lower than in the younger patients, with 44% as opposed to 57% (p=0.016). The most interesting difference, which accounted for the overall inferior outcome, was the duration of progression-free life in patients achieving a complete response: it was 35 months in the younger as opposed to 16.1 months in the elderly (p=0.024). Further, less intensive treatment at recurrence may further contribute to poorer outcome [2]. The biological basis for early recurrence after complete responses in the elderly remains obscure, but may involve host rather than tumor factors.

In the present issue of Oncology Research and Treatment, Lee and colleagues from Japan report on “Prognosis factors in Japanese elderly patients with primary CNS-lymphoma treated with non-radiation, intermediate-dose methotrexate-containing regimen” [3]. This is an extension of a series previously published [4]. The authors adopted the current trend of omitting whole brain radiotherapy from the primary treatment of these patients [5] and treated their patients with an “intermediate dose” methotrexate-based regimen containing 1 g/m² intravenous methotrexate on days 1, 10, and 20, 40 mg/m² i.v. ranimustine on day 1, 60 mg/m² oral procarbacine from days 1 to 7, and i.v. or oral methylprednisolone at a dose of 120 mg/m² every other day from days 1 to 20 and then at a dose of 60 mg/m² from days 21 to 45. Further, 15 mg methotrexate and 40 mg cytarabine were given intrathecally on days 1, 5, 10 and 15. This was followed by a similarly designed maintenance therapy. Using this regimen, progression-free survival and overall survival rates at 3 years were 29.8% and 56.2%. On univariate analysis, age >75 years, Karnofsky performance score <70, altered mentation and creatinine clearance > 90 ml/min were significantly associated with inferior outcome. On multivariate analysis, only increased creatinine clearance and altered mentation remained significant.
Although the authors discuss various approaches to interpret their data, it seems inescapable to conclude that high creatinine clearance reflecting intact renal function could only be a negative prognostic factor because these patients were underdosed with methotrexate. The treatment regimen they employed has the major weakness that it does not account for renal function. In contrast, in the G-PCNSL-SG-1 trial, the methotrexate dose was governed by the glomerular filtration rate [1], and we had reported early on that this is very well feasible in elderly patients with PCNSL [6]. Although only very few patients appeared to have received whole brain radiotherapy at progression, the authors report that they did not observed any delayed neurotoxicity. This is a surprising finding, given that they also used intrathecal chemotherapy, but information on how this was assessed is sparse.

In perspective, it is also noteworthy that the age cut off of 60 may not be fully adequate since more intensive regimens with a full methotrexate dose are probably warranted in most patients at least until the age of 70. For future trials, the age cut-off, which is necessary, should probably be supplemented by frailty scores in order to avoid undertreatment of elderly patients who are able to tolerate standard high-dose methotrexate chemotherapy.

Michael Weller, MD
Zurich, Switzerland

References


